U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H26N2S
Molecular Weight 314.4899
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERGOLIDE

SMILES

CCCN1C[C@@]([H])(C[C@]2([H])c3cccc4c3c(C[C@]21[H])c[nH]4)CSC

InChI

InChIKey=YEHCICAEULNIGD-MZMPZRCHSA-N
InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.scripintelligence.jp/wp-content/uploads/2014/05/12-January-2005-Heart-valve-disease-warning-for-pergolide-in-Europe.pdf | https://www.medicines.org.uk/emc/PIL.2413.latest.pdf?isAttachment=true&documentid=2413 | https://www.ncbi.nlm.nih.gov/pubmed/23769407

neurologist. The label warned against using doses of more than 5mg a day, whether alone or in combination with levodopa. However the marketing of this drug finally stopped in France in May 2011 and sales elsewhere in Europe ceased eventually.

Originator

Curator's Comment:: # Eli Lilly

Approval Year

TargetsConditions
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
209 ng/mL
0.5 mg 3 times / day steady-state, oral
dose: 0.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
472 ng/mL
1 mg 3 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
127 ng/mL
0.25 mg 3 times / day steady-state, oral
dose: 0.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1094 ng × h/mL
0.5 mg 3 times / day steady-state, oral
dose: 0.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2392 ng × h/mL
1 mg 3 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
573 ng × h/mL
0.25 mg 3 times / day steady-state, oral
dose: 0.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.8 h
0.5 mg 3 times / day steady-state, oral
dose: 0.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9%
138 μg single, oral
dose: 138 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.05 mg single, oral
Recommended
Dose: 0.05 mg
Route: oral
Route: single
Dose: 0.05 mg
Sources:
unhealthy, 46 - 75
Health Status: unhealthy
Age Group: 46 - 75
Sex: M+F
Sources:
Disc. AE: Rash, Syncope...
AEs leading to
discontinuation/dose reduction:
Rash (grade 2-3)
Syncope (grade 3)
Sources:
1 mg 3 times / day steady, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: steady
Dose: 1 mg, 3 times / day
Sources:
unhealthy, 46 - 75
Health Status: unhealthy
Age Group: 46 - 75
Sex: M+F
Sources:
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Disc. AE: Diarrhea, Dyskinesia...
AEs leading to
discontinuation/dose reduction:
Diarrhea (1%)
Dyskinesia (1%)
Dystonia (1%)
Headache (1%)
Liver disorder (1%)
Nausea and vomiting (2.9%)
Parkinsonism aggravated (1%)
Sleep disorder (1%)
Urinary incontinence (1%)
Sources:
14 mg multiple, oral
Overdose
unhealthy
Other AEs: Movements involuntary, Tingling...
Other AEs:
Movements involuntary (grade 3)
Tingling (grade 3)
Sources:
19 mg multiple, oral
Overdose
unhealthy
Other AEs: Hallucinations...
60 mg single, oral
Overdose
healthy
Other AEs: Vomiting, Hypotension...
7 mg single, oral
Overdose
unhealthy
Other AEs: Palpitations, Hypotension...
7 mg single, oral
Overdose
unhealthy
Other AEs: Ventricular extrasystoles...
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Disc. AE: Drug-induced hallucinosis...
Other AEs: Drug-induced hallucinosis...
AEs leading to
discontinuation/dose reduction:
Drug-induced hallucinosis (grade 3, 3%)
Other AEs:
Drug-induced hallucinosis (14%)
Sources:
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Other AEs: Hallucinations, Confusion...
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Other AEs: Daytime sleepiness...
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Other AEs: Pleuritis, Pleural effusion...
Other AEs:
Pleuritis (rare)
Pleural effusion (rare)
Pleural fibrosis (rare)
Pericarditis (rare)
Pericardial effusion (rare)
Cardiac valvulopathy (rare)
Retroperitoneal fibrosis (rare)
Sources:
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Other AEs: Daytime sleepiness, Hypotension symptomatic...
Other AEs:
Daytime sleepiness
Hypotension symptomatic (10%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Rash grade 2-3
Disc. AE
0.05 mg single, oral
Recommended
Dose: 0.05 mg
Route: oral
Route: single
Dose: 0.05 mg
Sources:
unhealthy, 46 - 75
Health Status: unhealthy
Age Group: 46 - 75
Sex: M+F
Sources:
Syncope grade 3
Disc. AE
0.05 mg single, oral
Recommended
Dose: 0.05 mg
Route: oral
Route: single
Dose: 0.05 mg
Sources:
unhealthy, 46 - 75
Health Status: unhealthy
Age Group: 46 - 75
Sex: M+F
Sources:
Diarrhea 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Dyskinesia 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Dystonia 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Headache 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Liver disorder 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Parkinsonism aggravated 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Sleep disorder 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Urinary incontinence 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Nausea and vomiting 2.9%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Movements involuntary grade 3
14 mg multiple, oral
Overdose
unhealthy
Tingling grade 3
14 mg multiple, oral
Overdose
unhealthy
Hallucinations grade 3
19 mg multiple, oral
Overdose
unhealthy
Agitation
60 mg single, oral
Overdose
healthy
Hypotension
60 mg single, oral
Overdose
healthy
Vomiting
60 mg single, oral
Overdose
healthy
Hypotension
7 mg single, oral
Overdose
unhealthy
Palpitations
7 mg single, oral
Overdose
unhealthy
Ventricular extrasystoles
7 mg single, oral
Overdose
unhealthy
Drug-induced hallucinosis 14%
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Drug-induced hallucinosis grade 3, 3%
Disc. AE
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Confusion 1.8%
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Hallucinations 7.8%
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Daytime sleepiness common
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Cardiac valvulopathy rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Pericardial effusion rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Pericarditis rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Pleural effusion rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Pleural fibrosis rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Pleuritis rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Retroperitoneal fibrosis rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Daytime sleepiness
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Hypotension symptomatic 10%
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Restless legs syndrome in the older adult: diagnosis and management.
2002
[Use of dopamine agonists in the treatment of Parkinson's disease].
2002
DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.
2002
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
2002
Choosing the right dopamine agonist for patients with Parkinson's disease.
2002
Elastic vesicles: interaction with human skin and drug transport.
2002
Effects of pergolide on blood pressure and tissue injury in DOCA-salt hypertension.
2002
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
2002
[The evolution of use of anti-Parkinson drugs in Spain].
2002 Apr 1-15
[Pergolide-induced pleural effusion in a patient with juvenile parkinsonism].
2002 Aug
Discrimination of morphine- and haloperidol-induced muscular rigidity and akinesia/catalepsy in simple tests in rats.
2002 Aug 21
Valvular heart disease in patients taking pergolide.
2002 Dec
Drug-related valvular heart disease: here we go again: will we do better this time?
2002 Dec
Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide.
2002 Dec
[Pergolide: a useful agonist for the treatment of Parkinson disease].
2002 Jul
Pergolide-induced lung disease in patients with Parkinson's disease.
2002 Jul
Transdermal delivery of pergolide from surfactant-based elastic and rigid vesicles: characterization and in vitro transport studies.
2002 Jul
Delayed visual loss following pergolide treatment of a prolactinoma.
2002 Jun
Dopamine receptor agonists for treating prolactinomas.
2002 Jun
[Multiple latency test in a patient with episodes of sleep induced by pergolide].
2002 Jun 16-30
Sleep attacks in patients taking dopamine agonists: review.
2002 Jun 22
Pergolide protects dopaminergic neurons in primary culture under stress conditions.
2002 May
Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies.
2002 May
Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum: counteraction by a NTR1-like receptor antagonist.
2002 May 7
Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.
2002 Nov
Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002 Nov
Dopamine agonist monotherapy in Parkinson's disease.
2002 Nov 30
Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).
2002 Nov-Dec
Muscarinic agonist-mediated increases in serum corticosterone levels are abolished in m(2) muscarinic acetylcholine receptor knockout mice.
2002 Oct
The effect of pergolide on cognitive performance of young and middle-aged rats.
2002 Sep
Gateways to Clinical Trials.
2002 Sep
[Cutaneous vasculitis during pergolide mesylate treatment].
2002 Sep
Pergolide-induced pleuropulmonary fibrosis.
2002 Sep-Oct
Cognitive effects of the dopamine receptor agonist pergolide.
2003
Dopamine agonists induce episodes of irresistible daytime sleepiness.
2003
[Gilles de la tourette syndrome: clinical spectrum and management].
2003 Apr 1-15
Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor.
2003 Feb
Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
2003 Feb
Tic reduction with pergolide in a randomized controlled trial in children.
2003 Feb 25
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
2003 Jan
Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice.
2003 Jan
The in vitro transport of pergolide from surfactant-based elastic vesicles through human skin: a suggested mechanism of action.
2003 Jan 9
The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans.
2003 Mar
[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease.
2003 Mar
The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.
2003 May
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
2003 May
Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
2003 May 9
Patents

Sample Use Guides

In Vivo Use Guide
Administration of Pergolide mesylate tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
Route of Administration: Oral
Pergolide (10 umol/L) depolarized PASMC
Name Type Language
PERGOLIDE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
PERGOLIDE [INN]
Common Name English
PERGOLIDE [WHO-DD]
Common Name English
PERGOLIDE [MI]
Common Name English
PERGOLIDE [VANDF]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 108197
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
LIVERTOX 762
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
WHO-ATC N04BC02
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
NDF-RT N0000000117
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
NDF-RT N0000175767
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
CFR 21 CFR 520.1705
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
NCI_THESAURUS C66884
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
WHO-VATC QN04BC02
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
NDF-RT N0000007620
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
NCI_THESAURUS C38149
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
Code System Code Type Description
RXCUI
8047
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY RxNorm
PUBCHEM
47811
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
MERCK INDEX
M8547
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL531
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
MESH
D010479
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
DRUG BANK
DB01186
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
WIKIPEDIA
PERGOLIDE
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
NCI_THESAURUS
C61886
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
EPA CompTox
66104-22-1
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
IUPHAR
48
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
INN
4651
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
CAS
66104-22-1
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
DRUG CENTRAL
2105
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
FDA UNII
24MJ822NZ9
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY
EVMPD
SUB09725MIG
Created by admin on Fri Jun 25 23:37:41 UTC 2021 , Edited by admin on Fri Jun 25 23:37:41 UTC 2021
PRIMARY